

I. Remarks


A) In compliance with 37 C.F.R. § 1.821, Applicants respectfully request entry of the enclosed "Sequence Listing" into the instant specification. This Sequence Listing conforms to the requirements of 37 C.F.R. 1.821- 1.824. This Sequence Listing comprises a substitute paper copy of the Sequence Listing in accordance with 37 C.F.R. § 1.821(c) and a substitute computer readable form of the Sequence Listing in the form of a compact disk in accordance with 37 C.F.R. § 1.821(e). In accordance with 37 C.F.R. § 1.821(f), Applicants believe that the sequence listing information recorded in computer readable form (compact disk) is identical to the written (paper copy) of the sequence listing. Applicants also submit herein the statement required under 37 C.F.R. § 1.821(g) that the sequence listing information recorded in computer readable form (compact disk) contains no new matter.

II. Conclusion

No fee is deemed necessary in connection with the filing of this communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

1/19/2007
Date

Respectfully submitted,



Jennifer D. Tousignant
Agent for Applicants
Registration No. 54,498
Telephone: (508) 270-2499
Facsimile: (508) 872-5415

GENZYME CORPORATION
15 Pleasant Street Connector
P.O. Box 9322
Framingham, Massachusetts 01701-9322